Nov 13, 2019
Boehringer, Lilly, SGLT-2 inhibitor, T1D, Setback
- Boehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes ― the EMDAC voted 14 to 2 that the benefits of empagliflozin 2.5 mg do not outweigh the risks to support approval
ベーリンガーインゲルハイムとリリーは１型糖尿病のインスリン投与成人患者に対するエンパグリフロジン2.5ｍｇの上乗せ投与に関するFDA諮問委員会の結果を発表。14対2で非承認を勧告。